NASDAQ$ANIK

Anika Therapeutics Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Anika had a positive start to 2023 with revenue growth, driven by OA Pain Management and Joint Preservation and Restoration.

Anika Therapeutics reported solid top line performance in Q1 2023, with double-digit growth in Joint Preservation and Restoration and solid growth in OA Pain Management. The company is on track for the full market release of RevoMotion Reverse Shoulder system in late 2023 and the launch of a regenerative rotator cuff patch system in 2024.

  • Revenue from veterinary products is now reported in the Non-Orthopedic product family.
  • OA Pain Management revenue increased by 8%.
  • Joint Preservation and Restoration revenue increased by 11%.
  • The company is driving adoption of the X-Twist Fixation System.

Headline financials

Total Revenue

$37.9M

Previous: $36.7M+3.4%
EPS (adj)

-$0.36

Previous: -$0.11-227.3%
Capital Expenditures

-$1.39M

Previous: -$1.33M-4.8%
Free Cash Flow

-$11.7M

Previous: -$4.26M-175.6%
Net Income

-$10.4M

Previous: -$2.93M-252.9%
Operating Income

-$12.6M

Previous: -$3.55M-253.2%
Gross Profit

$22.8M

Previous: $21.8M+4.8%
Cash & Equivalents

$79.7M

Previous: $90.3M-11.7%
Total Assets

$339M

Previous: $342M-0.9%
Stock-Based Comp

$3.72M

Previous: $2.55M+46.1%

Revenue & EPS history

Anika · Revenue · Quarterly

$37.9M

Q1 2023+3.4%vs Q1 2022
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

The Company continues to expect its overall revenue for fiscal year 2023 to be between $158 million and $163 million, representing growth of 1% to 4% compared to 2022, as growth in OA Pain Management and Joint Preservation and Restoration is offset by lower ancillary Non-Orthopedic revenues.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.1%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.8%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+32.1%

Q3 2019

Best reaction

-33.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-18.8%-4.7%-4.8%
Q4 2025+16.8%+31.6%+30.5%
Q3 2025+0.8%-0.5%+2.1%
Q1 2025-20.7%-23.2%-23.0%
Q4 2024-11.1%-7.3%-20.3%
Q3 2024-33.0%-34.0%-28.2%
Q2 2024-1.0%-3.6%-5.4%
Q1 2024-10.9%-9.9%-9.1%
Q4 2023-4.8%-2.0%-3.1%
Q3 2023+7.4%+6.7%+15.2%
Q2 2023-4.9%-12.7%-18.0%
Q1 2023-2.8%-3.2%+3.2%
Q4 2022-18.0%-17.4%-10.4%
Q3 2022+0.3%+5.3%+6.3%
Q2 2022-4.9%-2.7%-6.0%
Q1 2022-4.9%-3.8%+1.1%
Q4 2021-15.9%-18.0%-20.1%
Q3 2021+3.1%-8.2%-12.8%
Q2 2021+1.0%+0.8%+1.3%
Q1 2021+1.3%+2.8%+10.9%
Q4 2020-10.5%-12.1%+3.9%
Q3 2020-3.3%+0.2%+7.6%
Q2 2020+0.3%-8.7%+2.9%
Q1 2020-9.9%-12.2%+9.1%
Q4 2019+0.4%+0.1%-39.5%
Q3 2019+32.1%+21.5%+3.7%
Q2 2019+29.1%+31.0%+37.2%
Q1 2019+19.6%+21.5%+15.9%
Q4 2018-15.3%-18.8%-26.5%
Q3 2018-11.0%-13.6%-13.9%
Q2 2018+18.6%+15.0%+20.8%
Q1 2018-22.9%-15.7%-8.6%
Q4 2017-4.0%-11.3%-17.4%
Q3 2017-8.0%-9.2%-8.0%
Q2 2017+7.1%+6.0%+9.3%
Q1 2017-5.5%-1.8%+0.4%
Q4 2016-5.0%-5.1%-16.4%
Q3 2016+2.0%+2.7%+8.0%
Q2 2016-5.0%-2.3%-6.7%
Q1 2016+0.5%
Q4 2015+11.2%
Q3 2015+12.5%
Q2 2015+3.2%
Q1 2015-7.5%
Q4 2014-10.7%
Q3 2014+1.0%
Q2 2014+4.1%
Q1 2014+7.7%
Q4 2013+26.9%
Q3 2013+6.5%
Q2 2013+21.9%
Q1 2013-1.8%
Q4 2012+16.6%
Q3 2012-7.7%
Q2 2012+24.4%
Q1 2011+0.6%
Q1 2012+2.8%
Q4 2009+1.5%
Q4 2011+1.5%
Q3 2011+7.0%
Q3 2010+7.0%
Q2 2010-3.4%
Q4 2010-3.4%
Q2 2011-3.4%
Q1 2010-1.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro